U.S. patent application number 12/347471 was filed with the patent office on 2010-08-12 for mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof.
This patent application is currently assigned to Commissariat a I'Energie Atomique. Invention is credited to Isabelle Bourgault-Villada, Jean-Gerard Guillet, Bernard Maillere, Sandra Pouvelle-Moratille.
Application Number | 20100203080 12/347471 |
Document ID | / |
Family ID | 8862980 |
Filed Date | 2010-08-12 |
United States Patent
Application |
20100203080 |
Kind Code |
A1 |
Maillere; Bernard ; et
al. |
August 12, 2010 |
Mixture of Peptides Derived from E6 and/or E7 Papillomavirus
Proteins and Uses Thereof
Abstract
The invention concerns a mixture of peptides derived from the E6
and/or E7 proteins of a papillomavirus involved in cervix of uterus
cancer, such as HPV16, HPV18, HPV30, HPV31, HPV32, HPV33, HPV34,
HPV35, HPV39, HPV40, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52,
HPV56, HPV57, and HPV58, for example, as well as its uses as
medicine (in immunogenic compositions, capable of stimulating the
production of anti-HPV T CD4+ lymphocytes in vivo and hence useful
for vaccination against uterine of uterus cancer and in other
cancers) or as diagnostic reagent of HPV-specific T lymphocytes, in
particular for assessing the immune condition of patients. The
invention also concerns a mixture of peptides derived from E6
and/or E7 proteins of a papillomavirus involved in benign skin
lesions (for example warts), such as HPV10, HPV3 or HPV4 and its
uses as medicine.
Inventors: |
Maillere; Bernard;
(Versailles, FR) ; Bourgault-Villada; Isabelle;
(Paris, FR) ; Pouvelle-Moratille; Sandra; (Sainte
Genevieve Des Bois, FR) ; Guillet; Jean-Gerard;
(Paris, FR) |
Correspondence
Address: |
MORGAN LEWIS & BOCKIUS LLP
1111 PENNSYLVANIA AVENUE NW
WASHINGTON
DC
20004
US
|
Assignee: |
Commissariat a I'Energie
Atomique
Paris
FR
Institut National de la Sante et de la Recherche Medicale
(INSERM)
Paris
FR
|
Family ID: |
8862980 |
Appl. No.: |
12/347471 |
Filed: |
December 31, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10476570 |
Apr 26, 2004 |
7488791 |
|
|
PCT/FR02/01533 |
May 3, 2002 |
|
|
|
12347471 |
|
|
|
|
Current U.S.
Class: |
424/202.1 ;
424/204.1; 435/372.3; 435/7.94; 530/324; 530/326; 530/327 |
Current CPC
Class: |
Y02A 50/412 20180101;
Y02A 50/30 20180101; C07K 14/005 20130101; C12N 2710/20022
20130101; G01N 33/505 20130101; A61K 2039/58 20130101; G01N
2333/025 20130101; A61P 31/20 20180101; C12N 2710/20034 20130101;
A61P 35/00 20180101; A61K 39/12 20130101 |
Class at
Publication: |
424/202.1 ;
424/204.1; 530/326; 530/324; 530/327; 435/372.3; 435/7.94 |
International
Class: |
A61K 39/12 20060101
A61K039/12; C07K 7/08 20060101 C07K007/08; C07K 14/025 20060101
C07K014/025; A61K 39/295 20060101 A61K039/295; A61P 31/20 20060101
A61P031/20; C12N 5/0783 20100101 C12N005/0783; C12Q 1/02 20060101
C12Q001/02 |
Foreign Application Data
Date |
Code |
Application Number |
May 4, 2001 |
FR |
01 05980 |
Claims
1. A mixture of peptides derived from an E6 protein and/or from an
E7 protein of an HPV involved in cervical cancer or benign lesions
of the skin, characterized in that each of the peptides included in
said mixture binds to at least one HLA-DRB1 (1st gene) molecule the
frequency of which is greater than 5% in the Caucasian population
and, optionally, to at least one HLA-DRB3, HLA-DRB4 or HLA-DRB5
(2nd gene) molecule, with a binding activity<1 000 nM,
preferably <800 nM, said mixture of peptides binding to at least
eight HLA class II molecules, the frequency of which is greater
than 5% in the Caucasian population, encoded by the alleles
selected from the group consisting of the alleles HLA DRB1*0101,
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501
(DR1, DR3, DR4, DR7, DR11, DR13 and DR15 molecules) (1st gene) and
the alleles DRB3*0101, DRB4*0101 and DRB5*0101 (B3, B4 and B5) (2nd
gene).
2. The mixture of peptides according to claim 1, characterized in
that the peptides derived from an E6 protein of HPV are derived
from HPV16 and are selected from the group consisting of: (a) a
peptide included between positions 14 and 16, selected from the
group consisting of the peptide corresponding to positions 14-34
and the peptide corresponding to positions 14-46 (SEQ ID Nos. 8,
19), (b) the peptide corresponding to positions 30-50 (SEQ ID No.
10), (c) a peptide included between positions 44 and 67, selected
from the group consisting of the peptide corresponding to positions
45-67 and the peptide corresponding to positions 44-67 (SEQ ID Nos.
26, 27), (d) the peptide corresponding to positions 61-80 (SEQ ID
No. 11), (e) a peptide included between positions 76 and 119,
selected from the group consisting of the peptide corresponding to
positions 76-95, the peptide corresponding to positions 91-110 and
the peptide corresponding to positions 91-119 (SEQ ID Nos. 12, 35,
13), (f) a peptide included between positions 118-140, selected
from the group consisting of the peptide corresponding to positions
118-140 and the peptide corresponding to positions 121-140 (SEQ ID
Nos. 40, 41), (g) the peptide corresponding to positions 135-158
(SEQ ID No. 44), of the E6 protein of HPV16, and (h) the peptides,
preferably of 15 to 20 amino acids, exhibiting an amino acid
sequence having at least 60% identity or at least 80% similarity,
and preferably at least 70% identity or at least 99% similarity,
with the peptides defined in (a)-(g), said peptides being identical
in size, included in the peptides defined in (a)-(g) or else
completely or partially overlapping these peptides, with the
exclusion of the peptides corresponding to positions 15-44, 46-67,
80-108 and 118-139 of the E6 protein of HPV16 (SEQ ID Nos.
53-56).
3. The mixture of peptides according to claim 1 or claim 2,
characterized in that the peptides derived from an E7 protein are
derived from HPV16 and are selected from the group consisting of
the peptide corresponding to positions 1-20, the peptide
corresponding to positions 7-27, the peptide corresponding to
positions 65-87 and the peptide corresponding to positions 78-98 of
said E7 protein of HPV16 and the peptides, preferably of 15 to 20
amino acids, exhibiting an amino acid sequence having at least 60%
identity or at least 80% similarity, and preferably at least 70%
identity or at least 99% similarity, with the above peptides, said
peptides being identical in size, or included in the above peptides
or else overlapping these peptides, with the exclusion of the
peptides corresponding to positions 3-25 and 79-97 of the E7
protein of HPV16 (SEQ ID Nos. 57, 58).
4. The mixture of peptides according to any one of claims 1 to 3,
characterized in that it is selected from the group consisting of
the following mixtures: a mixture of peptides derived from the E6
protein of HPV16, comprising: the peptide corresponding to
positions 14-34 or to positions 14-46, the peptide corresponding to
positions 30-50 and the peptide corresponding to positions 44-67 or
to positions 45-67; a mixture of peptides derived from the E6
protein of HPV16, comprising: the peptide corresponding to
positions 61-80, the peptide corresponding to positions 76-95 and
the peptide corresponding to positions 91-119; a mixture of
peptides derived from the E7 protein of HPV16, comprising: the
peptide corresponding to positions 1-20 and the peptide
corresponding to positions 7-27; a mixture of peptides derived from
the E7 protein of HPV16, comprising: the peptide corresponding to
positions 65-87 and the peptide corresponding to positions 78-98;
and the mixtures comprising one of the mixtures of peptides derived
from the E6 protein HPV16 and one of the mixtures derived from the
E7 protein of HPV16.
5. An immunogenic anti-HPV16 composition, characterized in that it
comprises a mixture of peptides derived from an E6 protein of HPV
and/or a mixture of peptides derived from an E7 protein of HPV,
according to any one of claims 1 to 4, combined with at least one
pharmaceutically acceptable vehicle and, optionally, with at least
one adjuvant.
6. The composition according to claim 5, characterized in that said
peptides are either in the form of lipopeptides, or incorporated
into a recombinant virus or a viral vector for gene therapy, or
included in a protein, or chemically modified.
7. The composition according to claim 5 or claim 6, characterized
in that said mixture of peptides is combined: with one or more
peptides or lipopeptides containing one or more CD8+ epitopes, and
more particularly the CD8+ epitopes derived from an HPV protein, in
particular from an HPV16 protein, and/or, with other peptides
comprising multiple CD4+ epitopes, such as the tetanus toxin TT
peptide (positions 830-846), the Influenza hemagglutinin HA peptide
(positions 307-319), PADRE and the Plasmodium falciparum LSA3
peptide, and/or with one or more peptides or lipopeptides
containing one or more B epitopes, more particularly B epitopes
derived from an HPV16 protein.
8. An immunogenic composition, characterized in that it
advantageously comprises the sequences encoding the peptides as
defined in claims 1 to 4.
9. A vaccine, characterized in that it includes an immunogenic
composition according to any one of claims 5 to 8.
10. A peptide derived from an E6 protein of HPV, in particular of
HPV16, and/or from an E7 protein of HPV, in particular of HPV16,
characterized: in that it contains a CD4+ epitope capable of having
a binding activity<1 000 nM, preferably <800 nM, with respect
to at least one HLA II (HLA-DR) molecule predominant in Caucasian
populations (1st gene and/or 2nd gene), as defined in claims 1 to
6, of being recognized by CD4+ T lymphocytes specific for said
peptides, and of stimulating CD4+ T lymphocytes specific for said
peptides, and in that it is selected from the group consisting of
the fragments of sequence SEQ ID Nos. 8 to 18, 21-25, 28-34, 36-39,
42-43 and 45-52, corresponding respectively to the following
peptides of the E6 protein of HPV16: the peptide E6 (14-34 or
14-45), the peptide E6 (30-50), the peptide E6 (61-80), the peptide
E6 (76-95), the peptide E6 (91-119) and the peptides E6 (20-34,
24-38, 28-42, 31-45, 36-50, 42-56, 50-64, 55-69, 76-90, 78-92,
81-95, 84-98, 89-103, 93-107, 97-111, 101-115, 124-138, 130-144),
or to the following peptides of the E7 protein of HPV16: the
peptide E7 (1-20), the peptide E7 (7-27), the peptide E7 (60-74),
the peptide E7 (65-87), the peptide E7 (78-98) and the peptides E7
(6-20, 9-23, 13-27, 65-79, 67-81, 72-86, 77-91, 84-98).
11. A diagnostic reagent, characterized in that it is selected from
the group consisting of the peptides as defined in claims 1 to 4 or
the peptides as claimed in claim 10, said peptides optionally being
labeled or complexed, in the form of multimeric complexes.
12. A method for evaluating the immune state of an individual,
characterized in that it comprises a step of detecting the presence
of CD4+ T cells specific for the E6 and/or E7 peptides as defined
in claims 1 to 4, using an ELISPOT assay, a T cell proliferation
assay or an assay using multimeric complexes.
13. A method for sorting HPV16-specific T lymphocytes,
characterized in that it comprises at least the following steps:
incubating a suspension of cells to be sorted, or bringing it into
contact, for 1 to 3 hours, with one or more tetramers formed from
multimeric complexes made up of the E6 and/or E7 peptides as
defined in claims 1 to 4 and 10/soluble and biotinylated HLA II
molecule, and conjugated to streptavidin labeled with a
fluorochrome, analyzing by flow cytometry, and sorting the
tetramer-labeled cells.
14. The mixture of peptides according to claim 2, characterized in
that said peptides as defined in h) are selected from the group
consisting of the peptides corresponding respectively to positions
20-34, 24-38, 28-42, 31-45, 36-50, 42-56, 50-64, 55-69, 76-90,
78-92, 81-95, 84-98, 89-103, 93-107, 97-111, 101-115, 124-138 and
130-144 of the E6 protein of HPV16 (SEQ ID Nos. 21-25, 28-34,
36-39, 42-43).
15. The mixture of peptides according to claim 3, characterized in
that said peptides are selected from the group consisting of the
peptides corresponding respectively to positions 6-20, 9-23, 13-27,
65-79, 67-81, 72-86, 77-91 and 84-98 of the E7 protein of HPV16
(SEQ ID Nos. 45-52).
Description
[0001] The present invention relates to a mixture of peptides
derived from the E6 and/or E7 proteins of a papillomavirus involved
in cervical cancer, such as HPV16 (papillomavirus genotype 16),
HPV18, HPV30, HPV31, HPV32, HPV33, HPV34, HPV35, HPV39, HPV40,
HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, HPV56, HPV57 and HPV58,
for example, and also to uses thereof as a medicinal product (in
immunogenic compositions capable of stimulating the production of
anti-HPV CD4+ T lymphocytes in vivo, and therefore useful for
immunization against cervical cancer and in other cancers) or as a
reagent for diagnosing T lymphocytes specific for an HPV, in
particular for evaluating the immune state of patients.
[0002] The present invention also relates to a mixture of peptides
derived from the E6 and/or E7 proteins of a papillomavirus involved
in benign lesions of the skin (warts for example), such as HPV10,
HPV3 and HPV4, and to uses thereof as a medicinal product.
[0003] Human papillomaviruses (HPVs) induce benign lesions of the
skin and of the mucous membranes, but are also involved in the
induction of malignant lesions. They have mainly been involved in
cervical cancer, which constitutes, throughout the world, the
second most common cause of death from cancer in women.
[0004] They also contribute to the development of certain cancers
of the penis, of the anus and of the oropharynx. The DNA of these
viruses is in fact very commonly detected by PCR in biopsies from
patients (1). 20 to 50% of cancers of the penis and 70% of cancers
of the anus reveal the presence of HPV DNA.
[0005] There are in fact more than 100 different gentotypes of
papillomavirus, each having its own pathogenicity. The association
between infection with HPV and cervical cancer in fact varies
according to genotypes. The low or zero malignant
transformation-risk strains such as the HPV6 and HPV11 viruses are
distinguished from the high-risk strains such as HPV16 and HPV18
viruses. Whatever the country, HPV16 is found in 40 to 60% of
cervical cancers, whereas HPV18 is present in 10 to 20% of cases.
Most of the other patients suffering from cervical cancer are
infected with HPV31, HPV33 or HPV45.
[0006] For 1% of patients, no papillomavirus DNA is detected.
[0007] Experiments consisting of in vitro immortalization of
keratinocytes with HPV DNA have revealed that two genes (E6 and E7)
are mainly responsible for the cell transformation. In these
experiments, the DNA derived from high-risk viral strains is
capable of transforming the cells, whereas the low-risk strains are
not capable of doing this. The E6 protein binds to p53, which has
tumor-suppressing activity, and induces its degradation. The E7
protein binds to the pRb protein, which also has tumor-suppressing
activity. These activities are higher for the E6 and E7 proteins of
high-risk strains than for the low-risk strains. In addition, the
pRb and p53 genes are mutated and inactive in cervical cell lines
which are not infected with HPV, whereas this is not the case in
infected lines. All of these observations strongly suggest that the
E6 and E7 proteins are key components of HPV infection and of the
induction of cancerous states.
[0008] In the absence of antiviral treatments specific for HPV
infections, the development of anti-HPV vaccines constitutes one of
the promising approaches for combating the forms of cancer induced
by these viruses.
[0009] The use of attenuated or inactivated forms of viruses is,
however, difficult to apply due, firstly, to the current lack of
means for producing the virus and, secondly, to the presence in its
genome of transforming genes.
[0010] An approach based on peptides or subunits therefore appears
to be very advantageous. In particular, it is known that suitably
chosen peptides are capable of recruiting both cytotoxic T
lymphocytes (CTLs) and helper Tlymphocytes of the Th1 type directed
specifically against the transformed cells.
[0011] In this context, the E6 and E7 proteins constitute preferred
targets since they contribute directly to the cancerization of
cells, and their early expression after infection persists in the
transformed cell.
[0012] Various immunization strategies using peptides derived from
these two proteins have thus been recommended.
[0013] These strategies are based on the fact that CD4+ T
lymphocytes play a major role in establishing the immune responses
and in particular of the CTLs. Recent studies have shown that they
are involved, via CD40 molecules, in the activation of dendritic
antigen-presenting cells which are required for stimulation of the
specific CTLs (J. P. Ridge et al., Nature, 1998, 393, 474; S. P.
Schoenberger et al., Nature, 1998, 393, 480; S. R. Bennett et al.,
Nature, 1998, 393, 478; R. E M. Toes et al., Semin. Immunol., 1998,
10, 443).
[0014] The activation of the CD4+ T lymphocytes takes place through
the presentation of the viral peptides by the HLA II molecules
carried by the antigen-presenting cells (APCs). These peptides,
called T epitopes, result from the proteolytic degradation of the
viral antigens by the APC. They are variable in length, generally
from 13 to 25 amino acids, and have a sequence which makes them
capable of binding to the HLA II molecules.
[0015] It is now established that a peptide, T epitope, is capable,
to the same extent as the native antigen, of stimulating, in vitro,
CD4+ T lymphocytes which are specific for it, or of recruiting them
in viva.
[0016] T epitopes are therefore sufficient to induce a CD4+
response. However, one of the major problems which limits the use
of these peptides is that their sequence varies from one individual
to another, due to the polymorphism of HLA II molecules, which are
heterodimers expressed on the antigen-presenting cells (APCs) and
which present to the CD4+ T lymphocytes the T epitopes of said
antigens. These molecules are capable of binding a considerable
repertoire of peptides having very different sequences, which
allows them to present to the T cells several peptides per
antigen.
[0017] Four different types of HLA II molecule exist per
individual: 2 HLA-DR, 1 HLA-DQ and 1 HLA-DP; the HLA-DR molecule,
the .beta.-chain of which is encoded by the DRB1 gene (1st gene),
is the most highly expressed. There are currently listed more than
200 different alleles for DRB1, which define various antigens or
types, as summarized in table I below.
TABLE-US-00001 TABLE 1 Molecules expressed by various HLA-DRB1
alleles Antigen Allele Alias DR1 DRB1*0101 DR1 DR3 DRB1*0301 DR3w17
DR4 DRB1*0401 DR4w4 DRB1*0405 DR4w15 DR7 DRB1*0701 DR7 DR8
DRB1*0802 DR8w2 DR9 DRB1*0901 DR9 DR11 DRB1*1101 DR5w11 DR12
DRB1*1201 DR5w12 DR13 DRB1*1301 DRB1*1302 DR6w19 DR15 DRB1*1501
DR2w2b
[0018] Each allele has its own binding properties; the wide
specificity of the HLA II molecules and the existence of several
isoforms and of a polymorphism mean that each individual
recognizes, in an antigen, a set of peptides the nature of which
depends on the HLA II molecules which characterize it. Since a
large number of HLA II alleles exist, a large number of T epitopes,
specific for each allele, therefore exist for a given antigen.
[0019] In addition, the distribution of the alleles in a given
population is not homogeneous: for example, in the French
population, which corresponds to a mainly Caucasian population,
only 7 alleles of the DRB1 locus exceed 5%; these are the alleles:
DRB1*0101, DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301
and DRB1*1501, which represent 64% of the population (4). These
same alleles are also in the majority in other European
populations, where their frequency ranges from 53% (Spain) to 82%
(Denmark), and also in North America (55-58%).
[0020] The HLA-DRB3, -DRB4 and -DRB5 molecules (2nd gene), which
are HLA-DR molecules wherein the .beta.-chain is not encoded by the
DRB1 gene, are also present with high allelic frequencies in the
various Caucasian populations: 9.2% for DRB3*0101 (B3), 28.4% for
DRB4*0101 (B4) and 7.9% for DRB5*0101 (B5). They therefore cover,
by themselves, 45% of the allelic frequency in Caucasian
populations.
[0021] The peptides present in a peptide sequence and which bind
all these alleles include the T epitopes of the majority of the
Caucasian population.
[0022] One of the most commonly used means for defining helper CD4+
T epitopes is to measure the ability of the peptides to cause
proliferation of the mononuclear cells of individuals having been
in contact with the antigen under consideration.
[0023] A certain number of documents propose a selection of
epitopes derived from the E6 or E7 proteins of HPV16, which can be
used to produce a vaccine: [0024] International application WO
00/14244 (Connaught Laboratories Ltd) recommends, to obtain a
specific immunity without producing any risks of oncogenic
transformation, the use of constructs (vectors) wherein a certain
number of T epitopes derived both from E6 and from E7 are linked
together. More precisely, the antigens can be in the form of whole
proteins or of T epitopes. For example, the T epitope of the E6
protein is preferably the epitope corresponding to positions 29-38
of said protein and the preferred epitopes of the E7 protein are
those corresponding respectively to positions: 11-20, 49-57, 82-90,
86-93; the use of an E7 protein detoxified by deletion of the Rb
protein-binding site is also envisioned. [0025] Application EP 0
451 550 (Behringwerke) describes seroactive epitopes and in
particular epitopes derived from the E6 protein or from the E7
protein of HPV16, and also a vaccine containing one or more of said
epitopes. [0026] Patent EP 0 561 885 (University of Queensland and
CSL Ltd) describes a subunit vaccine against the HPV16
papillomavirus, which comprises the sequence DRAHYNI of the E7
protein (positions 48-54), considered to induce an immune response
significantly greater than other epitopes. [0027] Patent
application 0 386 734 (Behringwerke) describes two dominant
immunogenic regions in the E7 protein of HPV16, corresponding
respectively to positions 12-27 and 36-52, and their use in
reagents for detection. [0028] Luxton et al. have emphasized the
importance of cellular immunity in the control of genital
infections with HPV and have, consequently, studied the
proliferative T response to HPV infections; insofar as immunization
of mice with peptides derived from the E6 and E7 proteins of HPV16
protects against a virulent challenge consisting of
HPV16-transformed cancerous cells, they have in particular shown
the advantage of the E7 protein of HPV16 and have sought to
identify T epitopes in this protein. To do this, they have produced
synthetic peptides of 15 amino acids, the sequence of which
overlaps by 5 amino acids, so as to obtain a series of peptides
representing the entire sequence of the E7 protein. They have shown
that the proliferative T response depends on the state of the
patient and that, in asymptomatic individuals, the peptides located
in the N- and C-terminal regions (peptides 1-34 and 70-98) induce
an immunological response, whereas this is not the case in the
patients exhibiting cervical dysplasia. They have mainly shown that
the E7 peptide 80-94 of the HPV16 genotype causes the cells of 6
individuals out of the 7 tested to proliferate (J. Gen. Virol.,
1996, 77, 1585) (see table II below). [0029] G. Strang et al. have
defined four T epitopes of HPV16, one of which is present in E6 (J.
Gen. Virol., 1990, 71, 423). [0030] A. Altmann et al. have isolated
E7-specific T lymphocyte lines from two patients and characterized
the peptides recognized (Eur. J. Cancer, 1992, 28, 326). The study
was carried out with synthetic peptides of 14 amino acids, the
sequence of which overlaps by 10 amino acids, so as to obtain a
series of peptides representing the entire sequence of the E7
protein. [0031] T. Tsukui et al. has studied the secretion of IL2
by cells in the blood, in 140 HPV16+ patients having various stages
of lesion (Cancer Res., 1996, 56, 3967). [0032] M. Nakagawa et al.
have mainly observed that peptide 24-45 of E6 of the HPV16 genotype
causes proliferation of the cells of 13 individuals out of 63
tested (Immunol., 1996, 3, 205). They have also studied the
responses observed with the E7 protein and has shown that little
response is observed with this protein. [0033] A. S. Kadish et al.
has studied the proliferative response of the cells of HPV16+
patients to E6 and E7 peptides (Cancer Inst., 1997, 89, 1285).
[0034] T. D. de Gruijl et al. have studied the proliferation of
cells from patients infected with HPV and have observed that, among
the peptides covering the sequence of the E7 protein of the HPV16
virus, peptide 67-98 stimulates the cells of a majority of patients
(Cancer Res., 1998, 58, 1700).
[0035] All the E6 and E7 sequences identified as being T epitopes
in the patients studied are illustrated in table II.
TABLE-US-00002 TABLE II HPV16 peptides Documents (positions)
Properties WO 00/14244 E6: 29-38 E7: 11-20, 49-57, 82-90, 86-93 EP
0 451 550 E6: 7-37 E7: 6-26, 9-19, 7-21, 10-23, 36-52, 40-54 EP 0
561 885 E7: 48-54, 44-54, 44-62, 44-57, 44-56, 44-60, 44-48, 38-41,
10-14, 11-14 EP 0 375 555 E7: 45-58 EP 0 386 734 E7: 12-27, 12-23,
12-20, 12-19 and 36-52 Strang E6: 42-57 Recognized by
DR7-restricted et al. (14) clone Altmann E7: 5-18 Recognized by
line from a DR1 et al. (15) DR11 patient E7: 17-34 Recognized by
line from a DR4 DR13 patient E7: 69-82 Recognized by clone from a
DR4 DR13 patient Tsukui Secretion of IL2 (activation of et al. (17)
cells) by patients E6: 1-45 0/140 E6: 59-112 6/140 E6: 111-158
11/140 E7: 1-35 3/140 E7: 27-60 4/140 E7: 51-98 7/140 Luxton
Proliferation of cells from et al. (16) patients (CIN or normal)
E7: 1-14 0/31 CIN and 1/15 normal E7: 10-24 0/31 CIN and 3/15
normal E7: 20-34 0/31 CIN and 0/15 normal E7: 25-49 3/31 CIN E7:
30-44 2/31 normal E7: 40-54 0 CIN and 0 normal E7: 45-64 2/31 CIN
and 1/15 normal E7: 55-74 2/31 CIN and 1/15 normal E7: 70-98 4/31
CIN and 7/15 normal Nakagawa Proliferation of cells from et al.
(18) patients (CIN or normal) E6: 4-29 3/22 CIN and 12/65 normal
E6: 24-45 1/22 CIN and 15/65 normal E6: 109-122 1/22 CIN and 8/65
normal E7: 21-30 0/22 CIN and 5/65 normal E7: 44-57 3/22 CIN and
9/65 normal E7: 62-79 3/22 CIN and 10/65 normal Kadish
Proliferation of cells from et al. (19) patients (CIN or normal)
E6: 1-31 17/48 E6: 22-51 17/46 E6: 42-71 8/43 E6: 62-91 0/30 E6:
82-111 5/34 E6: 102-131 14/43 E6: 122-151 19/48 E6: 142-159 17/49
E6: 17-31 12/23 E6: 117-131 12/23 E6: 137-151 9/23 E7: 62-80 11/35
E7: 72-97 19/48 De Gruijl E7: 1-32 8/28 et al. (20) E7: 19-56 10/28
E7: 43-80 10/28 E7: 67-98 17/28
[0036] Considerable differences are observed between the studies,
reflecting the relative imprecision of this approach. It is in fact
difficult, in view of the diversity of the responses observed, to
define T epitope sequences for the entire population. These
sequences are adapted only to the patients involved in these
studies. These differences in response can be explained, firstly,
by the representativeness of the samples, which is not evaluated.
In particular, in the studies where the patients are not typed for
their HLA molecules, no one knows whether the various alleles are
represented according to the frequencies in the general population.
A response, common to many patients, to a particular peptide may
therefore result from a bias in the sampling and not from the
effective ability of a peptide to be recognized by all the
patients. Furthermore, in the case of infection with HPV, the
persistence of the antigen may induce a state of immune tolerance
against the T epitopes of the virus, those best recognized by the T
cells, as has been shown in a mouse model transgenic for the E7
protein of HPV (T. Doan et al., J. Virol., 1999, 73, 6166). In this
respect, it may be noted that the response is often weaker in the
patients who have eliminated the virus compared to the infected
patients (T. Tsukui et al., 1996, mentioned above). In this
context, the most advantageous epitopes might have disappeared from
the immune response, which would be maintained for less stimulatory
determinants but which would not succeed in eliminating the
virus.
[0037] These proliferation assays are therefore insufficient to
define sequences suitable for the entire population.
[0038] Thus, it emerges from the various studies that the peptides
that helper T lymphocytes recognize are difficult to define due to
the polymorphism of the HLA II molecules.
[0039] In addition, to date, immunization trials in women to induce
anti-HPV immunity have not made it possible to obtain clinically
satisfactory results. Eight patients suffering from cervical cancer
were immunized with a dose of vaccinia virus recombined with the
genes encoding the E6 and E7 proteins (L. K. Borysiewicz et al.,
Lancet., 1996, 347, 1523). A cytotoxic response was detected only
transiently and in only one patient.
[0040] The results obtained with peptides have also not been very
conclusive, with zero clinical effectiveness. M. E. Ressing et al.
(J. Immunother., 2000, 23, 255) and W. J. Van Driel et al. (Eur. J.
Cancer, 1999, 35, 946) have used a combination of two HPV peptides
and a helper peptide which is universal but not specific for the
virus. No cytotoxic response was induced. It is probable that the
lack of response is due to the inability of the constructs to
induce stimulation of both the HPV-specific helper CD4+ T
lymphocytes and the CD8+ lymphocytes.
[0041] Consequently, all the peptides proposed to date correspond
to T epitopes, which are specific only for particular individuals;
in fact, an inter-individual variability in T epitopes exists which
makes it difficult to choose molecules suitable for mass
immunization against HPV16; consequently, the peptides described
above are not suitable for the preparation of an immunogenic and
immunizing composition capable of stimulating anti-HPV16 CD4+ T
lymphocytes and generating a protective immune response, regardless
of the individual to be protected, since they do not stimulate a
protective CD4+ T response in all the individuals to be
treated.
[0042] For this reason, the inventors gave themselves the aim of
providing a set of peptides capable of being incorporated into an
immunogenic composition and of stimulating anti-HPV CD4+ T
lymphocytes, in the majority of European or North American
Caucasian individuals, so as to effectively induce a specific
proliferative response against components of the virus.
[0043] Such a set has the property of being effective in a large
number of individuals, whereas the peptides of the prior art are
active in some individuals and are inactive in most of the other
individuals, because the latter do not recognize the E6 and E7
proteins of HPV16 via the same determinants.
[0044] To do this, the inventors have selected peptides derived
from the E6 and E7 proteins of one of the abovementioned HPVs, in
particular of HPV16, restricted with respect to the HLA II
molecules predominant in Caucasian populations, and have found
that, in combination, the peptides selected effectively induce an
immunogenic and protective response in a large number of
individuals.
[0045] Consequently, a subject of the present invention is a
mixture of peptides derived from an E6 protein and/or from an E7
protein of an HPV involved in cervical cancer or benign lesions of
the skin, characterized in that each of the peptides included in
said mixture binds to at least one HLA-DRB1 (1st gene) molecule the
frequency of which is greater than 5% in the Caucasian population
and, optionally, to at least one HLA-DRB3, HLA-DRB4 or HLA-DRB5
(2nd gene) molecule, with a binding activity<1 000 nM,
preferably <800 nM, said mixture of peptides binding at least
eight HLA class II molecules, the frequency of which is greater
than 5% in the Caucasian population, encoded by the alleles
selected from the group consisting of the alleles HLA DRB1*0101,
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501
(DR1, DR3, DR4, DR7, DR11, DR13 and DR15 molecules) (1st gene) and
the alleles DRB3*0101, DRB4*0101 and DRB5*0101 (B3, B4 and B5) (2nd
gene).
[0046] Such a mixture of peptides makes it possible to obtain,
surprisingly, a proliferative CD4+ T response (stimulation of CD4+
T lymphocytes) and also stimulation of the CTL response, in a great
majority of the Caucasian population to be protected and whatever
the HPV concerned; it may therefore be considered that such a
mixture constitutes a first step toward a "universal" immunogenic
composition which can be used in a vaccine.
[0047] According to an advantageous embodiment of said mixture, the
peptides derived from an E6 protein of HPV are derived from HPV16
and are selected from the group consisting of:
[0048] (a) a peptide included between positions 14 and 16, selected
from the group consisting of the peptide corresponding to positions
14-34 and the peptide corresponding to positions 14-46 (SEQ ID Nos.
8, 19),
[0049] (b) the peptide corresponding to positions 30-50 (SEQ ID No.
10),
[0050] (c) a peptide included between positions 44 and 67, selected
from the group consisting of the peptide corresponding to positions
45-67 and the peptide corresponding to positions 44-67 (SEQ ID Nos.
26, 27),
[0051] (d) the peptide corresponding to positions 61-80 (SEQ ID No.
11),
[0052] (e) a peptide included between positions 76 and 119,
selected from the group consisting of the peptide corresponding to
positions 76-95, the peptide corresponding to positions 91-110 and
the peptide corresponding to positions 91-119 (SEQ ID Nos. 12, 35,
13),
[0053] (f) a peptide included between positions 118-140, selected
from the group consisting of the peptide corresponding to positions
118-140 and the peptide corresponding to positions 121-140 (SEQ ID
Nos. 40, 41),
[0054] (g) the peptide corresponding to positions 135-158 (SEQ ID
No. 44), of the E6 protein of HPv16, and
[0055] (h) the peptides, preferably of 15 to 20 amino acids,
exhibiting an amino acid sequence having at least 60% identity or
at least 80% similarity, and preferably at least 70% identity or at
least 99% similarity, with the peptides defined in (a)-(g), said
peptides being identical in size, or included in the peptides
defined in (a)-(g) or else completely or partially overlapping
these peptides, with the exclusion of the peptides corresponding to
positions 15-44, 46-67, 80-108 and 118-139 (SEQ ID Nos. 53-56) of
the E6 protein of HPV16.
[0056] The identity of a sequence with respect to a reference
sequence is assessed as a function of the percentage of amino acid
residues which are identical, when the two sequences are aligned so
that they correspond to one another to a maximum.
[0057] A peptide having an amino acid sequence having at least X %
identity with a reference sequence comprising Y amino acids is
defined, in the present invention, as a peptide the sequence of
which can include up to Y--X' alterations per Y amino acids of the
reference sequence and reformulated for a sequence of 100 amino
acids.
[0058] The similarity of a sequence with respect to a reference
sequence is assessed as a function of the percentage of amino acid
residues which are identical or which differ by conservative
substitutions, when these two sequences are aligned so that they
correspond to one another to a maximum. For the purpose of the
present invention, the term "conservative substitution" is intended
to mean the substitution of an amino acid with another which
exhibits similar chemical properties (size, charge or polarity),
which generally does not modify the functional properties of the
peptide.
[0059] Advantageously, the peptides derived from an E6 protein of
HPV of said mixture, as defined in (h), are selected from the group
consisting of: [0060] the peptides of 15 amino acids included in
the peptide corresponding to positions 14-34 or overlapping this
peptide, chosen from the peptides corresponding respectively to
positions 20-34, 24-38 and 28-42 (SEQ ID Nos. 21-23), [0061] the
peptides of 15 amino acids included in the peptide corresponding to
positions 30-50 or overlapping this peptide, chosen from the
peptides corresponding respectively to positions 31-45 and 36-50
(SEQ ID Nos. 24-25); [0062] the peptides of 15 amino acids included
in the peptide corresponding to positions 45-67 or overlapping this
peptide, chosen from the peptides corresponding respectively to
positions 42-56, 50-64 and 55-69 (SEQ ID Nos. 28-30); [0063] the
peptides of 15 to 17 amino acids included in the peptide
corresponding to positions 76-95 or overlapping this peptide,
chosen from the peptides corresponding respectively to positions
76-90, 78-92, 81-95 and 84-98 (SEQ ID Nos. 31-34); [0064] the
peptides of 15 amino acids included in the peptide corresponding to
positions 91-110 or overlapping this peptide, chosen from the
peptides corresponding, respectively, to positions 89-103, 93-107,
97-111 and 101-115 (SEQ ID Nos. 36-39); [0065] the peptides of 15
amino acids included in the peptide corresponding to positions
121-140 or overlapping this peptide, chosen from the peptides
corresponding respectively to positions 124-138 and 130-144 (SEQ ID
Nos. 42-43).
[0066] According to another advantageous embodiment of said
mixture, the peptides derived from an E7 protein are derived from
HPV16 and are selected from the group consisting of the peptide
corresponding to positions 1-20, the peptide corresponding to
positions 7-27, the peptide corresponding to positions 65-87 and
the peptide corresponding to positions 78-98 of said E7 protein of
HPV16 (SEQ ID Nos. 14, 15, 17, 18) and the peptides, preferably of
15 to 20 amino acids, exhibiting an amino acid sequence having at
least 60% identity or at least 80% similarity, and preferably at
least 70% identity or at least 99% similarity, with the peptides as
defined above, said peptides being identical in size, or included
in the peptides as defined above or else overlapping these
peptides, with the exclusion of the peptides corresponding to
positions 3-25 and 79-97 of the E7 protein of HPV16 (SEQ ID Nos.
57, 58).
[0067] Advantageously, the peptides derived from an E7 protein of
said mixture, included in the peptides (SEQ ID Nos. 14, 15, 17, 18)
as defined above or else overlapping these peptides, are selected
from the group consisting of the peptides corresponding
respectively to positions 6-20, 9-23, 13-27, 65-79, 67-81, 72-86,
77-91 and 84-98 of the E7 protein of HPV16 (SEQ ID Nos. 45-52).
[0068] Particularly advantageously, said mixture of peptides
according to the invention is selected from the group consisting of
the following mixtures: [0069] a mixture of peptides derived from
the E6 protein of HPV16, comprising: the peptide corresponding to
positions 14-34 or to positions 14-46, the peptide corresponding to
positions 30-50 and the peptide corresponding to positions 44-67 or
to positions 45-67; [0070] a mixture of peptides derived from the
E6 protein of HPV16, comprising: the peptide corresponding to
positions 61-80, the peptide corresponding to positions 76-95 and
the peptide corresponding to positions 91-119; [0071] a mixture of
peptides derived from the E7 protein of HPV16, comprising: the
peptide corresponding to positions 1-20 and the peptide
corresponding to positions 7-27; [0072] a mixture of peptides
derived from the E7 protein of HPV16, comprising: the peptide
corresponding to positions 65-87 and the peptide corresponding to
positions 78-98; [0073] and the mixtures comprising one of the
mixtures of peptides derived from the E6 protein HPV16 and one of
the mixtures derived from the E7 protein of HPV16, as defined
above.
[0074] Specifically: [0075] the peptide E6 (14-34) binds with good
affinity to the DRB1*0301, 0701 and 1501 molecules, [0076] the
peptide E6 (30-50) binds with good affinity to the DRB1*0101, 0301,
0401, 1101, 1301 and 1501, DRB5*0101 and DRB4*0101 molecules,
[0077] the peptide E6 (61-80) binds with good affinity to the
DRB1*0301, 1101 and 1501, DRB3*0101 and DRB5*0101 molecules, [0078]
the peptide E6 (76-95) binds with good affinity to the DRB1*0101,
1101, 1301 and 1501, [0079] DRB5*0101 and DRB4*0101 molecules,
[0080] the peptide E6 (91-119) binds with good affinity to the
DRB1*0101, 0301, 0401, 0701 and 1501 and DRB5*0101 molecules,
[0081] the peptide E7 (1-20) binds with good affinity to the
DRB1*0101, 0301, 0401, 1101, 1301 and 1501, DRB5*0101 and DRB4*0101
molecules, [0082] the peptide E7 (7-27) binds with good affinity to
the DRB1*0101, 0301, 0401, 1101 and 1301, DRB3*0101, DRB5*0101 and
DRB4*0101 molecules, [0083] the peptide E7 (60-74) binds with good
affinity to the DRB1*0701 and DRB5*0101 molecules, [0084] the
peptide E7 (65-87) binds with good affinity to the DRB1*0101, 0301,
0401, 0701 and 1501 and DRB3*0101 molecules, [0085] the peptide E7
(78-98) binds with good affinity to the DRB1*0101, 0701, 1101 and
1501, DRB5*0101 and DRB4*0101 molecules.
[0086] The sequences of these various peptides are given in tables
III and IV below:
TABLE-US-00003 TABLE III Identification Peptide Sequence number
E6(1-22) MHQKRTAMFQDPQERPRKLPQL SEQ ID No. 59 E6(14-34)
ERPRKLPQLCTELQTTIHDII SEQ ID No. 8 E6(30-50) IHDIILECVYCKQQLLRREVY
SEQ ID No. 10 E6(45-67) LRREVYDFAFRDLCIVYRDGNPY SEQ ID No. 26
E6(61-80) YRDGNPYAVCDKCLKFYSKI SEQ ID No. 11 E6(76-95)
FYSKISEYRHYCYSLYGTTL SEQ ID No. 12 E6(91-110) YGTTLEQQYNKPLCDLLIRC
SEQ ID No. 35 E6(105-126) DLLIRCINCQKPLCPEEKQRHL SEQ ID No. 60
E6(121-140) EKQRHLDKKQRFHNIRGRWT SEQ ID No. 41 E6(135-158)
IRGRWTGRCMSCCRSSRTRRETQL SEQ ID No. 44 E7(1-20)
MHGDTPTLHEYMLDLQPETT SEQ ID No. 14 E7(7-27) TLHEYMLDLQPETTDLYCYEQ
SEQ ID No. 15 E7(21-40) DLYCYEQLNDSSEEEDEIDG SEQ ID No. 61
E7(35-55) EDEIDGPAGQAEPDRAHYNIV SEQ ID No. 62 E7(43-57)
GQAEPDRAHYNIVTF SEQ ID No. 63 E7(60-74) KCDSTLRLCVQSTHV SEQ ID No.
16 E7(65-87 LRLCVQSTHVDIRTLEDLLMGTL SEQ ID No. 17 E7(78-98)
TLEDLLMGTLGIVCPICSQKP SEQ ID No. 18
TABLE-US-00004 TABLE IV Peptide Sequence E6/2(14-34) E R P R K L P
Q L CT E L Q T T I H D I I E6/17-31 R K L P Q L CT E L Q T T I H
E6/20-34 P Q L CT E L Q T T I H D I I E6/24-38 T E L Q T T I H D I
I L E C V E6/28-42 T T I H D I I L E C V Y C K Q E613(30-50) I H D
I I L E C V YC K Q Q L L R R E V Y E6/31-45 H D I I L E C V YC K Q
Q L L E6/36-50 E C V YC K Q Q L L R R E V Y E614(45-67) L R R E V
YD F A F R D L C I V Y R D G N P Y E6/42-56 Q Q L L R R E V YD F A
F R D E6/50-64 YD F A F R D L C I V Y R D G E6/55-69 R D L C I V Y
R D G N P Y A V E6/6(76-95) F Y S K I S E Y R HY C Y S L Y G T T L
E6/76-90 F Y S K I S E Y R HY C Y S L E6/81-92 S K I S E Y R HY C Y
S L Y G E6/81-95 S E Y R HY C Y S L Y G T T L E6/84-98 R HY C Y S L
Y G T T L E Q Q E6/7(91-110) Y G T T L EQ Q Y N K P L C D L L I R C
E6/89-103 S L Y G T T L EQ Q Y N K P L E6/93-107 T T L EQ Q Y N K P
L C D L L E6/97-111 Q Q Y N K P L C D L L I R C I E6/101-115 K P L
C D L L I R C I N C Q K E6/9(121-140) E K Q R H L D K K QR F HNI R
G R WT E6/124-138 H L D K K QR F HNI R G R E6/130-144 QR F HNI R G
R WT G R C M E7/1(1-20) MH G D T P T L HEY ML D L Q P E T T E7/6-20
P T L HEY ML D L Q P E T T E7/2(7-27) T L HE Y ML D L QP E T T D L
Y C Y E Q E7/9-23 HE Y ML D L QP E T T D L Y E7/13-27 L D L QP E T
T D L Y C Y E Q E7/7(65-87) L R L C V Q S T H VD I R T L E D L L MG
T L E7/65-79 L R L C V Q S T H VD I R T L E7/67-81 L C V Q S T H VD
I R T L E D E7/72-86 T H VD I R T L E D L L MG T E7/8(78-98) T L E
D L L MG TL GI V C P I C S Q K P E7/77-91 R T L E D L L MG TL GI V
C E7/84-98 MG TL GI V C P I C S Q K P
[0087] Other peptides exhibit binding activities, but on a limited
number of molecules.
[0088] A subject of the present invention is also an immunogenic
anti-HPV composition, characterized in that it comprises a mixture
of peptides derived from an E6 protein of HPV and/or a mixture of
peptides derived from an E7 protein of HPV, as defined above,
combined with at least one pharmaceutically acceptable vehicle and,
optionally, with at least one adjuvant.
[0089] The adjuvants used are adjuvants conventionally used in
vaccine compositions, such as alumina hydroxide and squalene.
[0090] According to advantageous embodiment of said immunogenic
composition, said peptides are either in the form of lipopeptides,
or incorporated into a recombinant virus, a viral vector for gene
therapy (adenovirus, etc.), or included in a protein and in
particular a recombinant protein (Leclerc C. et al., Int. Rev.
Immunol., 1994, 11, 2, 123-132; Janssen R. et al., Int. Rev.
Immunol., 1994, 11, 2, 113-121), or chemically modified. In the
latter case, they comprise, fOr example, unnatural modifications
such as D amino acids, pseudopeptide bonds or modifications of the
C- or N-terminal ends.
[0091] The lipid moiety of the lipopeptide is in particular
obtained by addition of a lipid unit to an .alpha.-amino function
of said peptides or to a reactive function of the side chain of an
amino acid of the peptide moiety; it may comprise one or more
optionally branched or unsaturated C.sub.4-C.sub.20 fatty
acid-derived chains (palmitic acid, oleic acid, linoleic acid,
linolenic acid, 2-aminohexadecanoic acid, pimelautide,
trimetauxide) or a derivative of a steroid. The method for
preparing such lipopeptides is in particular described in
international applications WO 99/40113 and WO 99/51630. The
preferred lipid moiety is in particular represented by an
N.sup..alpha.-acetyl-lysine N.sup..epsilon. (palmitoyl) group, also
referred to as Ac-K(Pam).
[0092] According to another advantageous embodiment of said
immunogenic composition, said mixture of peptides is combined:
[0093] with one or more peptides or lipopeptides containing one or
more CD8+ epitopes (specifically recognized by cytotoxic T
lymphocytes and presented by HLA I molecules), and more
particularly the CD8+ epitopes derived from an HPV protein, in
particular from an HPV16 protein (Ressing et al., van Driel et al.)
and/or [0094] with other peptides comprising multiple CD4+
epitopes, such as the tetanus toxin TT peptide (positions 830-846),
the Influenza hemagglutinin HA peptide (positions 307-319), PADRE
(Pan DR Epitope, Alexandre J. et al., Immunity, 1994, 1, 9,
751-761) or the Plasmodium falciparum LSA3 peptide and/or [0095]
with one or more peptides or lipopeptides containing one or more B
epitopes, more particularly B epitopes derived from an HPV16
protein (Tindle et al.), specifically recognized by antibodies
directed against these epitopes.
[0096] The E6 and E7 peptides according to the invention, included
in the mixtures, as defined above were advantageously selected
using an HLA-DR/peptide binding assay comprising: [0097] purifying
the HLA-DR molecules of interest, i.e. those involving more than 5%
of a given population, and in particular the HLA DR1, DR3, DR4,
DR7, DR11, DR13 and DR15 molecules, [0098] incubating the HLA-DR
molecules thus purified with various concentrations of overlapping
fragments entirely covering the sequence of the E6 protein or of
the E7 protein and with a reagent R1 or tracer consisting of a
peptide fragment associated with a nonradioactive label, such as
biotin, and the sequence of which is different from said peptides;
the reagent R1 or tracer is chosen in such a way that it exhibits
an affinity with respect to one of the HLA-DR molecules of
interest, such that it may be used at a concentration<200 nM,
[0099] transferring the complexes obtained onto an ELISA-type plate
precoated with an antibody specific for all the HLA-DRs, [0100]
revealing the HLA-DR molecule/reagent R1 complexes attached to the
bottom of the plate by means of suitable conjugates, such as
streptavidin-phosphatase, and of a fluorescent substrate, [0101]
selecting the peptides comprising different epitopes, i.e. the most
representative of the various regions of interaction between the E6
protein or the E7 protein and the HLA-DR molecules, and [0102]
choosing the most suitable peptides, as a function of the frequency
of the alleles with respect to which they exhibit a binding
activity<1 000 nM, preferably <800 nM, corresponding to the
concentration of these peptides which inhibits 50% of the binding
of the reagent R1 (IC.sub.50).
[0103] These assays make it possible to unambiguously associate
with each allele of the 1st gene or of the 2nd gene the sequences
of the fragments capable of binding thereto or, on the contrary,
which do not bind thereto.
[0104] This approach makes it possible to define immunogenic
compositions including peptides which bind to the greatest number
of different HLA-DR molecules and which may thus be advantageously
protective for the majority of patients, even if their HLA
molecules are not known.
[0105] This approach also has the advantage of making it possible
to select peptides which are significantly more specific with
respect to HPV16 than the approaches seeking to select peptides on
the basis of their ability to stimulate CD4+ T lymphocytes
(proliferation assays).
[0106] The incubation conditions are specific to each HLA-DR
molecule (incubation time, pH, reagent R1, concentration of HLA-DR
or of peptide).
[0107] The reagent R1 is selected from the group consisting of the
following sequences: [0108] PKYVKQNTLKLAT (HA 306-318) (SEQ ID No.
1), specific for the alleles DRB1*0101, DRB1*0401, DRB1*1101,
[0109] EAEQLRAYLDGTGVE (A3 152-166) (SEQ ID No. 2), specific for
the allele DRB1*1501, [0110] AKTIAYDEEARGLE (MT 2-16) (SEQ ID No.
3), specific for the allele DRB1*0301, [0111] AAYAAAKAAALAA (YKL)
(SEQ ID No. 4), specific for the allele DRB1*0701, [0112]
TERVRLVTRHIYNREE (B1 21-36) (SEQ ID No. 5), specific for the allele
DRB1*1301, [0113] ESWGAVWRIDTPDKLTGPFT (LOL 191-210) (SEQ ID No.
6), specific for the allele DRB3*0101, and [0114] AGDLLAIETDKATI
(E2/E168) (SEQ ID No. 7), specific for the allele DRB4*0101.
[0115] Other reagents R1 can be used, in particular those described
in Southwood et al. (24).
[0116] As a variant, said immunogenic composition advantageously
comprises the sequences encoding the peptides as defined above.
[0117] In fact, the use of naked DNA for immunization constitutes
an effective vaccinal approach: it consists in injecting into the
host organism to be vaccinated a naked DNA encoding a protein
antigen; this DNA allows sustained synthesis of the antigen by the
host's cells and also long-lasting presentation of this antigen to
the immune system.
[0118] A subject of the present invention is also a vaccine,
characterized in that it includes an immunogenic composition as
defined above.
[0119] A subject of the present invention is also peptides derived
from an E6 protein of HPV, in particular of HPV16, and/or from an
E7 protein of HPV, in particular of HPV16, characterized: [0120] in
that they contain a CD4+ epitope capable of having a binding
activity<1 000 nM, preferably <800 nM with respect to at
least one HLA II (HLA-DR) molecule predominant in Caucasian
populations (1st gene and/or 2nd gene), as defined above, of being
recognized by CD4+ T lymphocytes specific for said peptides, and of
stimulating CD4+ T lymphocytes specific for said peptides, and
[0121] in that they are selected from the group consisting of the
fragments of sequence SEQ ID Nos. 8 to 18, 21-25, 2.alpha.-34,
36-39, 42-43 and 45-52, corresponding respectively to the following
peptides of the E6 protein of HPV16: the peptide E6 (14-34 or
14-45), the peptide E6 (30-50), the peptide E6 (61-80), the peptide
E6 (76-95), the peptide E6 (91-119) and the peptides E6 (20-34,
24-38, 28-42, 31-45, 36-50, 42-56, 50-64, 55-69, 76-90, 78-92,
81-95, 84-98, 89-103, 93-107, 97-111, 101-115, 124-138, 130-144),
or to the following peptides of the E7 protein of HPV16: the
peptide E7 (1-20), the peptide E7 (7-27), the peptide E7 (60-74),
the peptide E7 (65-87), the peptide E7 (78-98) and the peptides E7
(6-20, 9-23, 13-27, 65-79, 67-81, 72-86, 77-91, 84-98).
[0122] A subject of the present invention is a diagnostic reagent,
characterized in that it is selected from one of the E6 and E7
peptides as defined above, said peptides optionally being labeled
or complexed, in the form of multimeric complexes.
[0123] A subject of the present invention is also a method for
evaluating the immune state of an individual, characterized in that
it comprises a step of detecting the presence of CD4+ T cells
specific for the E6 and/or E7 peptides as defined above; said
detection is advantageously carried out using one of the following
assays: proliferation assay, ELISPOT assay [see, for example,
international application WO 99/51630 or Gahery-Segard et al. (27)]
or flow cytometry in the presence of multimeric complexes made up
of said E6 and/or E7 peptides.
[0124] More precisely: [0125] as regards the proliferation
assay:
[0126] A suspension of cells (PBMCs, CD8+ cell-depleted PBMCs, T
lymphocytes pre-enriched by a step of culturing in vitro with the
peptides selected according to the invention, or cloned T
lymphocytes) is cultured for 3 to 5 days in the presence of the
selected peptides and, as needed, of suitable presenting cells,
such as dendritic cells, autologous or heterologous PBMCs,
lymphoblastoid cells such as those obtained after infection with
the EBV virus or genetically modified cells. The cell proliferation
is measured by incorporation of tritiated thymidine into the DNA of
the cells. The peptides selected in accordance with the invention
make it possible to reveal, in the initial suspension, the presence
of cells specific for these peptides. [0127] as regards the ELISPOT
assay:
[0128] The ELISPOT assay makes it possible to reveal the presence
of T cells specific for a peptide selected in accordance with the
invention and secreting .gamma.-IFN.
[0129] More precisely, the T cells are revealed by measuring the
secretion of .gamma.-IFN after incubation of PBMCs from patients
with the peptides selected according to the invention, in
accordance with the method described in Gahery-Segard et al., 2000
(27). [0130] as regards the use of multimeric complexes, and in
particular of tetrameric complexes: [0131] a biological sample,
preferably peripheral blood mononuclear cells (PBMCs), is brought
into contact with tetrameric complexes produced from multimeric
complexes made up of E6 or E7 peptides as defined above--soluble
and biotinylated HLA class II molecule, and [0132] the labeled
cells are analyzed by flow cytometry.
[0133] Advantageously, prior to bringing the biological sample into
contact with said complex, it is enriched in CD4+ T cells by
bringing it into contact with anti-CD4 antibodies so as to enrich
said sample.
[0134] The tetramers are prepared as specified, for example, in E.
J. Novak et al. (J. Clin. Investig., 1999, 104, R63-R67) or in M.
J. Kuroda et al. (J. Virol., 2000, 74, 18, 8751-8756).
[0135] Briefly the tetramers are produced by incubating, for 72
hours at 37.degree. C. and in a 10 mM citrate phosphate buffer
containing 0.15 M NaCl, at a pH of between 4.5 and 7, soluble and
biotinylated HLA II molecules with a 10-fold excess of E6 or E7
peptides identified. and selected in accordance with the
invention.
[0136] The tetramerized form is obtained by adding streptavidin
labeled with a fluorochrome to the preparation in an amount four
times less (mole for mole) than HLA II molecules. The whole mixture
is incubated overnight at ambient temperature.
[0137] To use these tetramers, a suspension of cells (PBMCs, CD8+
cell-depleted PBMCs, T lymphocytes pre-enriched by a step of
culturing in vitro with the E6 or E7 peptides selected in
accordance with the present invention, or cloned T lymphocytes) is
brought into contact with one or more tetramers (10 to 20 mg/ml)
for 1 to 3 hours. After washing, the suspension is analyzed by flow
cytometry: the labeling of the cells with the tetramers is
visualized by virtue of the fact that these constructs are
fluorescent.
[0138] The flow cytometry makes it possible to separate the
tetramer-labeled cells from the nonlabeled cells and thus to
perform cell sorting.
[0139] A subject of the present invention is thus also a method for
sorting HPV16-specific T lymphocytes, characterized in that it
comprises at least the following steps: [0140] incubating a
suspension of cells to be sorted, or bringing it into contact, for
1 to 3 hours, with one or more tetramers formed from E6 and/or E7
peptide as defined above/soluble and biotinylated HLA II molecule
complexes, and conjugated to streptavidin labeled with a
fluorochrome, [0141] analyzing by flow cytometry, and [0142]
sorting the tetramer-labeled cells.
[0143] Besides the arrangements above, the invention also comprises
other arrangements which will emerge from the following
description, which refers to examples of implementation of the
method which is the subject of the present invention and also to
the attached drawing, in which:
[0144] FIG. 1 represents the proliferation and the .gamma.-IFN
secretion of cells from a patient suffering from bowenoid papulosis
and in whom the infection has been spontaneously resolved. The
patient is DRB1*1601/1501 DRB5*0101. The peptide E6 (45-67) is a
good ligand for DRB1*1501, and the peptide E7 (7-27) is a good
ligand for DRB5*0101 (see also table VIII).
[0145] It should be clearly understood, however, that these
examples are given purely by way of illustration of the subject of
the invention, of which they in no way constitute a limitation.
EXAMPLE 1
Various HPV Strains and their Percentage Identity with HPV16
TABLE-US-00005 [0146] Strains Pathology E6 E7 HPV18 Cervical cancer
63 40 HPV31 '' 72 81 HPV33 '' 71 70 HPV45 '' 63 44 HPV58 '' 71 69
HPV30 '' 59 50 HPV34 '' 67 56 HPV35 '' 79 83 HPV39 '' 61 41 HPV40
'' 44 40 HPV42 '' 50 53 PHV43 '' 48 HPV44 '' 47 52 HPV51 '' 67 45
HPV52 '' 69 68 HPV56 '' 63 44 HPV57 '' 48 44 HPV10 warts 47 84 HPV3
'' 46 56 HPV4 '' 38 69
EXAMPLE 2
Principle of the Binding Assays
[0147] Peptide Synthesis
[0148] The peptides chosen cover the sequence of the E6 protein or
of the E7 protein. All the peptides were synthesized according to
the Fmoc strategy by parallel solid-phase synthesis, purified by
HPLC and controlled by mass spectrometry (ES-MS).
[0149] Purification of HLA-DR Molecules
[0150] The HLA-DR molecules were purified from various homozygous
EBV lines by immunoaffinity. The method described in Southwood et
al. (24) can in particular be used. Their origin and the various
alleles which characterize them are described in table IV.
TABLE-US-00006 TABLE IV Lines Specificities DRB1 alleles Other DRB
alleles LG2 (14) HLA-DR1 DRB1*0101 -- HOM2 SCHU HLA-DR2 DRB1*1501
DRB5*0101 MAT (14) HLA-DR3 DRB1*0301 DRB3*0101 STEILIN BOLETH
HLA-DR4 DRB1*0401 DRB4*0101 PREISS (14) PITOUT (14) HLA-DR7
DRB1*0701 DRB4*0101 SWEIG (14) HLA-DR11 DRB1*1101 DRB3*0202 HHKB
(17) HLA-DR13 DRB1*1301 DRB3*0101
[0151] The monomorphic antibody specific for the HLA-DR molecules
is in particular that described in Southwood et al. (24) or that
described in Posch et al. (25). The antibodies are purified from
culture supernatants on protein A-sepharose columns. These
anti-bodies are coupled to sepharose 4B or protein A-sepharose
columns for purification of the HLA-DR molecules.
[0152] HLA-DR/Peptide Binding Assays
[0153] The assays for binding of the peptides to the HLA-DR
molecules are competition assays with immuno-enzymatic revelation,
initially developed by Hill on the HLA-DR molecule (26). They are
carried out in 96-well plates, which makes it possible to study
many samples in the same experiment. Briefly, the purified HLA-DR
molecules are incubated with a biotinylated peptide which serves as
a tracer and various concentrations of test peptide.
[0154] After incubation for 24 to 72 hours, these samples are
neutralized, and then 100 .mu.l of each sample are transferred onto
an ELISA plate precoated with the HLA-DR molecule-specific
monomorphic antibody. The HLA-DR molecule/biotinylated peptide
complexes, attached to the bottom of the plate via the HLA-DR
molecule-specific monomorphic antibody, are revealed by means of
streptavidin-phosphatase conjugate and a fluorescent substrate. The
activity of each peptide is characterized by the concentration of
this peptide which inhibits 50% of the binding of the biotinylated
peptide (IC.sub.50).
[0155] Choice and Optimization of the Binding Assays
[0156] Choice of Alleles (1st Gene)
[0157] The alleles studied are all the alleles of the French
population whose frequency exceeds 5% of the population.
[0158] They are the alleles DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*1101, DRB1*1301 and DRB1*1501 (table I). They
represent, by themselves, 53 to 82% of the alleles of Caucasian
populations and make up various specificities of the HLA-DR
series.
[0159] Choice of Alleles (2nd Gene)
[0160] The alleles studied are the alleles most commonly
encountered. They are the alleles HLA-DRB3*0101, HLA-DRB4*0101 and
HLA-DRB5*0101.
[0161] Assay Specificity
[0162] The choice of the biotinylated peptides is the determining
element of the assay specificity. Most of the cells used possess
two different HLA-DR molecules (encoded by two alleles) which are
both purified by an HLA-DR molecule-specific monomorphic antibody
and are both recognized by the same antibody. In order to
unambiguously study the binding of a peptide to the DRB1 allele, it
is necessary to be sure that the biotinylated peptide binds this
allele and does not bind the product of the other allele.
[0163] For this purpose, the peptides as defined as reagents R1
above were used.
[0164] Assay Conditions and Sensitivity
[0165] For each HLA-DRB1 molecule, the concentration of MHC II
molecules, the concentration of the biotinylated peptide, the
incubation pH and the incubation time were optimized as specified
in table V below.
TABLE-US-00007 TABLE V Protein Tracer Incuba- concen- concen- tion
tration tration Optimum time Alleles (.mu.g/ml) Tracers (nM) pH (h)
DRB1*0101 0.6 HA 306-318 10 6 24 DRB1*0301 2.3 MT 2-16 50 4.5 72
DRB1*0401 1.6 HA 306-318 30 6 24 DRB1*0701 0.4 YKL 10 5 24
DRB1*1101 1.3 HA 306-318 20 5 24 DRB1*1301 0.7 B1 21-36 200 4.5 72
DRB1*1501 0.5 A3 152-166 10 4.5 24
[0166] The sensitivity of each assay is reflected by the IC.sub.50
values observed with the nonbiotinylated peptides which correspond
to the tracers, and the results obtained are given in table VI
below.
TABLE-US-00008 TABLE VI Biotinylated IC.sub.50 Alleles Frequency
peptides Sequences (Nm) DRB1*0101 9.3 HA 306-318 PKYVKQNTLKLAT 31
DRB1*0401 5.6 HA 306-318 PKYVKQNTLKLAT 44 DRB1*1101 9.2 HA 306-318
PKYVKQNTILKLAT 38 DRB1*0701 14.0 YKL AAYAAAKAAALAA 34 DRB1*0301
10.9 MT 2-16 AKTIAYDEEARRGLE 100 DRB1*1301 6.0 B1 21-36
TERVRLVTRHIYNREE 330 DRB1*1501 8.0 A3 152-166 EAEQLRRAYLDGTGVE 14
DRB5*0101 7.9 HA 306-318 PKYVKQNTLKLAT 6.5 DRB3*0101 9.2 Lol
191-210 ESWGAVWRIDTPDKLTGPFT 5 DRB4*0101 28.4 E2/E168
AGDLLAIETDKATI 2
[0167] The frequencies indicated are the allelic frequencies in
France and are representative of those of the Caucasian population.
They are derived from Colombani (22).
[0168] Tables VIIa and VIIb below illustrate the binding activity
of the peptides according to the invention, measured under the
conditions specified above.
TABLE-US-00009 TABLE VIIa Binding activities of the selected E6 and
E7 peptides with respect to the HLA-DR molecules which are
predominant in the Caucasian population DR1 DR3 DR4 DR7 DR11 DR13
DR15 B3 B5 B4 E6/1 >10000 3500 >10000 >10000 >10000
>10000 >10000 10000 >10000 >10000 (1-22) E6/2 3500 550
>10000 225 10000 >10000 800 1450 >10000 >10000 (14-34)
E6/3 400 1000 450 1400 800 250 75 1500 3.5 700 (30-50) E6/4 50
>10000 2000 2330 125 >10000 225 2500 65 >10000 (45-67)
E6/5 1750 100 2500 10000 60 >10000 400 200 9.5 6500 (61-80) E6/6
3.5 >10000 5000 3500 150 300 24 >10000 120 27 (76-95) E6/7 30
200 90 500 2000 >10000 5.5 9500 50 6500 (91-110) E6/8 1750
>10000 3750 >10000 5000 5000 4000 >10000 30 70 (105-126)
E6/9 125 >10000 >10000 200 350 1130 >10000 >10000 85
>10000 (121-140) E6/10 200 >10000 17.5 10000 700 >10000
1600 >10000 10 4250 (135-158) E7/I 2500 >10000 300 >10000
1750 >10000 125 35 >10000 4 (1-20) E7/II 300 560 60 >10000
600 7500 1770 8.5 70 375 (7-27) E7/III >10000 4600 1750
>10000 >10000 >10000 5300 >10000 >10000 >10000
(21-40) E7/IV >10000 >10000 >10000 >10000 >10000
>10000 >10000 >10000 >10000 >10000 (33-55) E7/V
>10000 >10000 >10000 >10000 >10000 >10000 2000
>10000 2250 >10000 (43-57) E7/VI 5000 >10000 2000 900 7000
>10000 >10000 >10000 200 1950 (60-74) E7/VII 650 450 650
900 2000 >10000 470 850 2000 2000 (65-87) E7/VIII 800 >10000
2250 500 900 >10000 35 >10000 350 500 (78-98)
TABLE-US-00010 TABLE VIIb Binding activities of the selected E6 and
E7 peptides with respect to the HLA-DR molecules which are
predominant in a Caucasian population SEQ ID peptide No. e DR1 DR3
DR4 DR7 DR11 DR13 DR15 DRB3 DRB4 DRB5 E6/2 (14-34) No. 8 E6 17-31
No. 20 10000 6500 1750 E6 20-34 No. 21 45 >10000 >10000 7000
>10000 E6 24-38 No. 22 425 300 >10000 1500 300 >10000 950
>10000 >10000 E6 28-42 No. 23 45 >10000 1200 >10000
2000 >10000 450 4250 50 E6/3 (30-50) No. 10 E6 31-45 No. 24 65
>10000 2250 600 10000 750 >10000 95 E6 36-50 No. 25 38 2750
5000 525 >10000 225 >10000 15 E6/4 (45-67) No. 26 E6 42-56
No. 28 >10000 >10000 >10000 6000 375 3250 55 >10000 E6
50-64 No. 29 900 85 6500 1483 60 E6 55-69 No. 30 1500 250 55
>10000 E6/6 (76-95 No. 12 E6 76-90 No. 31 125 525 225 500
>10000 1050 E6 78-92 No. 32 225 1750 2250 120 >10000 1250 E6
81-95 No. 33 10 725 >10000 >10000 >10000 2500 E6 84-98 No.
34 2000 3250 7000 >10000 >10000 >10000 900 E6/7 (91-110)
No. 35 E6 89-103 No. 36 125 5000 1500 >10000 >10000 53
>10000 200 E6 93-107 No. 37 5 >10000 7750 18 325 E6 97-111
No. 38 575 1233 325 >10000 4000 5500 E6 101-115 No. 39 12 3000
25 350 150 5 E6/9 (121-140) No. 41 E6 124-138 No. 42 10 >10000
475 75 E6 130-144 No. 43 4 950 115 75 E7/1 (1-20) No. 14 E7 6-20
No. 45 750 >10000 175 1500 675 90 200 2000 E7/2 (7-27) No. 15 E7
9-23 No. 46 325 >10000 375 9500 65 >10000 >10000 E7 13-27
No. 47 4000 3500 4250 3500 10000 >10000 >10000 E7/7 (65-87)
No. 17 E7 65-79 No. 48 750 >10000 >10000 600 >10000
>10000 E7 67-81 No. 49 7000 >10000 7500 1500 950 >10000 E7
72-86 No. 50 25 900 100 2000 35 600 E7/8 (78-98) No. 18 E7 77-91
No. 51 5 55 >10000 >10000 700 E7 84-98 No. 52 20 1250 425
1750 90
[0169] The results are expressed in the form of concentrations
giving 50% inhibition of maximum binding. The unit is nM.
EXAMPLE 3
Proliferation Assay
[0170] To verify the stimulation of CD4+ T cell proliferation using
immunogenic composition according to the invention, a proliferation
assay is performed in vitro.
[0171] The cells (PBMCs) extracted from peripheral blood were
cultured in 96-well microplates in a proportion of 2.times.10.sup.5
cells per well, in a final volume of 200 .mu.l of complete medium.
The cells were or were not stimulated with 10 .mu.g/ml of a mixture
of peptides according to the invention. After culturing for 5 days
at 37.degree. C., the cells were incubated overnight with 0.25
.mu.Ci of [.sup.3H]-thymidine (Amersham, Life technology). The
cells were recovered and the [.sup.3H]-thymidine incorporation was
measured in a cellular DNA.
[0172] Stimulation of the CD4+ T cells is effectively observed.
[0173] Other cells can be used: CD8+ cell-depleted PBMCs, T cells
pre-enriched by a step of culturing in vitro with the peptides as
defined above, or cloned lymphocytes.
[0174] Briefly, the enriching protocol is as follows:
[0175] The PBMCs, separated on a Ficoll gradient, are cultured at
37.degree. C. in the presence of 0.1 to 10 mg/ml of peptides in
RPMI medium supplemented with 10% human serum. On the 7th and 11th
day of culturing, 50 units of recombinant human IL-2 are added to
the culture. The cells are harvested on the 14th day.
EXAMPLE 4
ELISPOT
[0176] The ELISPOT makes it possible to detect cells which are
specific for a peptide and which secrete a given cytokine.
[0177] 50 .mu.l/well of murine anti-human .gamma.-IFN antibody
diluted, in PBS buffer, to a concentration of 4 .mu.g/ml are
incubated in nitrocellulose-bottomed 96-well plates overnight at
4.degree. C. in a humid chamber.
[0178] The wells are washed with PBS and saturated with RPMI medium
containing 10% calf serum for 2 hours at 37.degree. C.
[0179] If needed, suitable presenting cells, such as autologous or
heterologous PBMCs, lymphoblastoid cells obtained after infection
with the EBV virus or genetically modified cells, are used and are
dispensed into the wells. The E6 or E7 peptides as defined in the
invention are then added at various concentrations (10, 5 and 1
.mu.g/ml).
[0180] The effector cells (PBMCs, CD8+ cell-depleted PBMCs, T
lymphocytes pre-enriched by a step of culturing in vitro with the
E6 or E7 peptides or both, or cloned lymphocytes) are added to the
96-well plates in a proportion of 20 000 cells/well.
[0181] The culture is incubated for 24 hours at 37.degree. C. in an
atmosphere containing 5% CO.sub.2.
[0182] The plates are then washed and incubated for 2 hours with
100 .mu.l of a rabbit antiserum specific for human .gamma.-IFN.
[0183] After washing, an anti-rabbit IgG antibody conjugated to
biotin then streptavidin conjugated to alkaline phosphatase are
added successively for 1 hour.
[0184] Finally, the spots are revealed by virtue of a chromogenic
substrate of alkaline phosphatase. These spots are counted under a
microscope. Negative controls are given by the wells containing no
peptides. The positive controls are provided by the wells
containing mitogenic agents such as ionomycin (500 ng/ml) and
phytohemagglutinin (PHA) (10 .mu.g/ml).
EXAMPLE 5
In Vivo Assay
[0185] The mixtures of peptides as defined above were assayed in
vivo, in patients having bowenoid papulosis. Bowenoid papulosis is
a cutaneous-mucosal infection due to HPV16 which affects young
women; it is a chronic and recurring disease, despite the
destructive treatments used. This disease is a vulvar
intraepithelial neoplasm grade 3 from the beginning (VIN 3), which
has the particularity of not progressing to an invasive
carcinoma.
[0186] The considerable infiltration of the epithelium by numerous
CD4+ lymphocytes suggests that these cells contribute to
controlling the stage of the disease and to preventing
invasion.
[0187] The results observed in a patient who had resolved the
infection herself are given by way of example in FIG. 1.
[0188] The proliferative response of the cells from 13 patients
having bowenoid papulosis, with respect to the peptides, was
studied.
[0189] The peptides recognized, in terms of proliferation, by the
CD4+ T lymphocytes were listed for each disease.
[0190] The results obtained are given in table VIII below.
[0191] This table shows the advantage of the peptides selected in
accordance with the present invention.
TABLE-US-00011 TABLE VIII Possible Reminder Possible Reminder
Patients 1st DR 2nd DR 1st DR 2nd DR Prolif DR IC.sub.50 ELISPOT DR
IC.sub.50 GUI 1601 (?) DRB5 1501 (?) DRB5 E6/2 1501 800 E6/4 1501
225 DRB5 >10 000 DRB5 65 E6/4 1501 225 E7/2 1501 1 770 DRB5 65
DRB5 70 E7/3 1501 5 300 DRB5 >10 000 CAR 701 (?) DRB4 E6/2 701
225 DRB4 >10 000 E7/2 701 >10 000 DRB4 375 JOU 1501 (?) DRB5
E6/2 1501 800 DRB5 >10 000 E6/4 1501 225 DRB5 65 E6/5 1501 400
DRB5 9.5 E6/10 1501 1 600 DRB5 10 E7/2 1501 1 770 DRB5 70 RIZ 1501
(?) DRB5 0404 or 0101 423 weak 1501 400 E6/5 DRB5 9.5 weak 1501 1
600 E6/10 DRB5 10 ROU 411 (?) DRB4 701 (?) DRB4 weak ALB 1301 (?)
DRB3 1101 (?) uninter- pretable LOK 1501 (?) DRB5 801 negative ALC
311 (?) DRB3 1501 (?) E6/2 1501 800 E6/2 1501 800 DRB5 >10 000
DRB5 >10 000 E6/4 1501 225 E6/4 1501 225 DRB5 65 E6/5 1501 400
DRB5 9.5 E6/7 1501 5.5 DRB5 50 E6/8 1501 4 000 DRB5 30 E7/2 1501 1
770 DRB5 70 E7/3 1501 5 300 DRB5 >10 000 E7/4 1501 >10 000
DRB5 >10 000 E7/7 1501 470 DRB5 2 000 E7/8 1501 35 DRB5 350 BRO
1101 (?) DRB3 1001 E6/2 1101 10 000 DRB3 1 450 E6/4 1101 125 DRB3 2
500 BLAI 1101 (?) DRB3 701 (?) DRB4 E6/2 1101 10 000 (?) DRB3 1 450
701 225 (?) DRB4 >10 000 E6/4 1101 125 (?) DRB3 2 500 701 2 330
(?) DRB4 >10 000 LEG 1501 (?) DRB5 801 (?) E6/2 1501 800 DRB5
>10 000 E6/7 1501 5.5 DRB5 60 E7/7 1501 470 DRB5 2 000 E6/10
1501 1 600 DRB5 10 CAI 701 (?) DRB4 1501 (?) DRB5 E6/2 1501 800
DRB5 >10 000 701 225 DRB4 >10 000 E6/4 1501 225 DRB5 65 701 2
330 DRB4 >10 000 DEL 701 (?) DRB4 E6/2 701 225 E6/2 701 225 DRB4
>10 000 DRB4 >10 000 E6/4 701 2 330 E6/4 701 2 330 DRB4
>10 000 DRB4 >10 000
BIBLIOGRAPHICAL REFERENCES
[0192] 1. Lowy D. R. et al., Proc. Natl. Acad. Sci. USA, 1994, 91,
2436. [0193] 2. Borysiewicz L. K. et al., Lancet, 1996, 347, 1523.
[0194] 3. Ressing M. E. et al., J. Immunother., 2000, 23, 255.
[0195] 4. Van Driel W. J. et al., Eur. J. Cancer, 1999, 35, 946.
[0196] 5. Ridge J. P., Nature, 1998, 393, 474. [0197] 6.
Schoenberger S. P. et al., Nature, 1998, 393, 480. [0198] 7.
Bennett S. R. et al., Nature, 1998, 393, 478. [0199] 8. Toes R. E.
M. et al., Semin. Immunol., 1998, 10, 443. [0200] 9. Tindle R. W.
et al., Proc. Natl. Acad. Sci. USA, 1991, 88, 5887. [0201] 10.
Azoury-Ziadeh R. K. et al., Viral. Immunol., 1999, 12, 297. [0202]
11. Hohn H. et al., J. Immunol., 1999, 163, 5715. [0203] 12. Hohn
H. et al., J. Virol., 2000, 74, 6632. [0204] 13. Bontkes H. J. et
al., J. Gen. Virol., 1999, 80, 409. [0205] 14. Strang G. et al., J.
Gen. Virol., 1990, 71, 423. [0206] 15. Altmann A. et al., Eur. J.
Cancer, 1992, 28, 326. [0207] 16. Luxton J. C. et al., J. Gen.
Viral., 1996, 77, 1585. [0208] 17. Tsukui T. et al., Cancer Res.,
1996, 56, 3967. [0209] 18. Nakagawa M. et al., Clin. Diagn. Lab.
Immunol., 1996, 3, 205. [0210] 19. Kadish A. S. et al., J. Natl.
Cancer Inst., 1997, 89, 1285. [0211] 20. de Gruijl T. D. et al.,
Cancer Res., 1998, 58, 1700. [0212] 21. Doan T. et al., J. Virol.,
1999, 74, 6166. [0213] 22. Colombani J., 1993, HLA: fonctions
immunitaires et applications medicales, Eds. John Libbey Eurotext.
[0214] 23. Ressing M. E. et al., J. Immunol., 1995, 154, 5934.
[0215] 24. Southwood et al., J. Immunol., 1998, 160, 3363-3373.
[0216] 25. Posch et al., Eur. J. Immunol., 1996, 26, 1884. [0217]
26. Hill et al., J. Immunol., 1994, 152, 2890. [0218] 27.
Gahery-Segard et al., J. Virol., 2000, 74, 1694.
Sequence CWU 1
1
63113PRTArtificial sequenceSynthetic peptide HA 306-318 1Pro Lys
Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr1 5 10215PRTArtificial
sequenceSynthetic peptide A3 152-166 2Glu Ala Glu Gln Leu Arg Ala
Tyr Leu Asp Gly Thr Gly Val Glu1 5 10 15314PRTArtificial
sequenceSynthetic peptide MT 2-16 3Ala Lys Thr Ile Ala Tyr Asp Glu
Glu Ala Arg Gly Leu Glu1 5 10413PRTArtificial sequenceSynthetic
peptide YKL 4Ala Ala Tyr Ala Ala Ala Lys Ala Ala Ala Leu Ala Ala1 5
10516PRTArtificial sequenceSynthetic peptide B1 21-36 5Thr Glu Arg
Val Arg Leu Val Thr Arg His Ile Tyr Asn Arg Glu Glu1 5 10
15620PRTArtificial sequenceSynthetic peptide LOL 191-210 6Glu Ser
Trp Gly Ala Val Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr1 5 10 15Gly
Pro Phe Thr 20714PRTArtificial sequenceSynthetic peptide E2/E168
7Ala Gly Asp Leu Leu Ala Ile Glu Thr Asp Lys Ala Thr Ile1 5
10821PRTArtificial sequenceSynthetic peptide E6 14-34 8Glu Arg Pro
Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr1 5 10 15Ile His
Asp Ile Ile 20932PRTArtificial sequenceSynthetic peptide E6 14-45
9Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr1 5
10 15Ile His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu
Leu 20 25 301021PRTArtificial sequenceDescription of the artificial
sequence peptide E6 30-50 10Ile His Asp Ile Ile Leu Glu Cys Val Tyr
Cys Lys Gln Gln Leu Leu1 5 10 15Arg Arg Glu Val Tyr
201120PRTArtificial sequenceSynthetic peptide E6 61-80 11Tyr Arg
Asp Gly Asn Pro Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe1 5 10 15Tyr
Ser Lys Ile 201220PRTArtificial sequenceSynthetic peptide E6 76-95
12Phe Tyr Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr1
5 10 15Gly Thr Thr Leu 201329PRTArtificial sequenceSynthetic
peptide E6 91-119 13Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro
Leu Cys Asp Leu1 5 10 15Leu Ile Arg Cys Ile Asn Cys Gln Lys Pro Leu
Cys Pro 20 251420PRTArtificial sequenceSynthetic peptide E7 1-20
14Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln1
5 10 15Pro Glu Thr Thr 201521PRTArtificial sequenceSynthetic
peptide E7 7-27 15Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu
Thr Thr Asp Leu1 5 10 15Tyr Cys Tyr Glu Gln 201615PRTArtificial
sequenceSynthetic peptide E7 60-74 16Lys Cys Asp Ser Thr Leu Arg
Leu Cys Val Gln Ser Thr His Val1 5 10 151723PRTArtificial
sequenceSynthetic peptide E7 65-87 17Leu Arg Leu Cys Val Gln Ser
Thr His Val Asp Ile Arg Thr Leu Glu1 5 10 15Asp Leu Leu Met Gly Thr
Leu 201821PRTArtificial sequenceSynthetic peptide E7 78-98 18Thr
Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile1 5 10
15Cys Ser Gln Lys Pro 201933PRTArtificial sequenceSynthetic peptide
E6 14-46 19Glu Arg Pro Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln
Thr Thr1 5 10 15Ile His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln
Gln Leu Leu 20 25 30Arg2015PRTArtificial sequenceSynthetic peptide
E6 17-31 20Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile
His1 5 10 152115PRTArtificial sequenceSynthetic peptide E6 20-34
21Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp Ile Ile1 5 10
152215PRTArtificial sequenceSynthetic peptide E6 24-38 22Thr Glu
Leu Gln Thr Thr Ile His Asp Ile Ile Leu Glu Cys Val1 5 10
152315PRTArtificial sequenceSynthetic peptide E6 28-42 23Thr Thr
Ile His Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln1 5 10
152415PRTArtificial sequenceSynthetic peptide E6 31-45 24His Asp
Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu1 5 10
152515PRTArtificial sequenceSynthetic peptide E6 36-50 25Glu Cys
Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu Val Tyr1 5 10
152623PRTArtificial sequenceSynthetic peptide E6 45-67 26Leu Arg
Arg Glu Val Tyr Asp Phe Ala Phe Arg Asp Leu Cys Ile Val1 5 10 15Tyr
Arg Asp Gly Asn Pro Tyr 202723PRTArtificial sequenceSynthetic
peptide E6 44-67 27Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Arg Asp
Leu Cys Ile Val1 5 10 15Tyr Arg Asp Gly Asn Pro Tyr
202815PRTArtificial sequenceSynthetic peptide E6 42-56 28Gln Gln
Leu Leu Arg Arg Glu Val Tyr Asp Phe Ala Phe Arg Asp1 5 10
152915PRTArtificial sequenceSynthetic peptide E6 50-64 29Tyr Asp
Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly1 5 10
153015PRTArtificial sequenceSynthetic peptide E6 55-69 30Arg Asp
Leu Cys Ile Val Tyr Arg Asp Gly Asn Pro Tyr Ala Val1 5 10
153115PRTArtificial sequenceSynthetic peptide E6 76-90 31Phe Tyr
Ser Lys Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu1 5 10
153215PRTArtificial sequenceSynthetic peptide E6 78-92 32Ser Lys
Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly1 5 10
153315PRTArtificial sequenceSynthetic peptide E6 81-95 33Ser Glu
Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu1 5 10
153415PRTArtificial sequenceSynthetic peptide E6 84-98 34Arg His
Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln1 5 10
153520PRTArtificial sequenceSynthetic peptide E6 91-110 35Tyr Gly
Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu1 5 10 15Leu
Ile Arg Cys 203615PRTArtificial sequenceSynthetic peptide E6 89-103
36Ser Leu Tyr Gly Thr Thr Leu Glu Gln Gln Tyr Asn Lys Pro Leu1 5 10
153715PRTArtificial sequenceSynthetic peptide E6 93-107 37Thr Thr
Leu Glu Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu1 5 10
153815PRTArtificial sequenceSynthetic peptide E6 97-111 38Gln Gln
Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile1 5 10
153915PRTArtificial sequenceSynthetic peptide E6 101-115 39Lys Pro
Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys1 5 10
154023PRTArtificial sequenceSynthetic peptide E6 118-140 40Cys Pro
Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His1 5 10 15Asn
Ile Arg Gly Arg Trp Thr 204120PRTArtificial sequenceSynthetic
peptide E6 121-140 41Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg
Phe His Asn Ile Arg1 5 10 15Gly Arg Trp Thr 204214PRTArtificial
sequenceSynthetic peptide E6 124-138 42His Leu Asp Lys Lys Gln Arg
Phe His Asn Ile Arg Gly Arg1 5 104315PRTArtificial
sequenceSynthetic peptide E6 130-144 43Gln Arg Phe His Asn Ile Arg
Gly Arg Trp Thr Gly Arg Cys Met1 5 10 154424PRTArtificial
sequenceSynthetic peptide E6 135-158 44Ile Arg Gly Arg Trp Thr Gly
Arg Cys Met Ser Cys Cys Arg Ser Ser1 5 10 15Arg Thr Arg Arg Glu Thr
Gln Leu 204515PRTArtificial sequenceSynthetic peptide E7 6-20 45Pro
Thr Leu His Glu Tyr Met Leu Asp Leu Gln Pro Glu Thr Thr1 5 10
154615PRTArtificial sequenceSynthetic peptide E7 9-23 46His Glu Tyr
Met Leu Asp Leu Gln Pro Glu Thr Thr Asp Leu Tyr1 5 10
154715PRTArtificial sequenceSynthetic peptide E7 13-27 47Leu Asp
Leu Gln Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln1 5 10
154815PRTArtificial sequenceSynthetic peptide E7 65-79 48Leu Arg
Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu1 5 10
154915PRTArtificial sequenceSynthetic peptide E7 67-81 49Leu Cys
Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu Asp1 5 10
155015PRTArtificial sequenceSynthetic peptide E7 72-86 50Thr His
Val Asp Ile Arg Thr Leu Glu Asp Leu Leu Met Gly Thr1 5 10
155115PRTArtificial sequenceSynthetic peptide E7 77-91 51Arg Thr
Leu Glu Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys1 5 10
155215PRTArtificial sequenceSynthetic peptide E7 84-98 52Met Gly
Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Lys Pro1 5 10
155330PRTArtificial sequenceSynthetic peptide E6 15-44 53Arg Pro
Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile1 5 10 15His
Asp Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu 20 25
305421PRTArtificial sequenceSynthetic peptide E6 46-67 54Arg Arg
Glu Val Tyr Asp Phe Ala Arg Asp Leu Cys Ile Val Tyr Arg1 5 10 15Asp
Gly Asn Pro Tyr 205529PRTArtificial sequenceSynthetic peptide E6
80-108 55Ile Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr
Thr Leu1 5 10 15Glu Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile
20 255622PRTArtificial sequenceSynthetic peptide E6 118-139 56Cys
Pro Glu Glu Lys Gln Arg His Leu Asp Lys Lys Gln Arg Phe His1 5 10
15Asn Ile Arg Gly Arg Trp 205723PRTArtificial sequenceSynthetic
peptide E7 3-25 57Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp
Leu Gln Pro Glu1 5 10 15Thr Thr Asp Leu Tyr Cys Tyr
205819PRTArtificial sequenceSynthetic peptide E7 79-97 58Leu Glu
Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys1 5 10 15Ser
Gln Lys5922PRTArtificial sequenceSynthetic peptide E6 1-22 59Met
His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro1 5 10
15Arg Lys Leu Pro Gln Leu 206022PRTArtificial sequenceSynthetic
peptide E6 105-126 60Asp Leu Leu Ile Arg Cys Ile Asn Cys Gln Lys
Pro Leu Cys Pro Glu1 5 10 15Glu Lys Gln Arg His Leu
206120PRTArtificial sequenceSynthetic peptide E7 21-40 61Asp Leu
Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser Glu Glu Glu Asp1 5 10 15Glu
Ile Asp Gly 206221PRTArtificial sequenceSynthetic peptide E7 35-55
62Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp Arg Ala1
5 10 15His Tyr Asn Ile Val 206315PRTArtificial sequenceSynthetic
peptide E7 43-57 63Gly Gln Ala Glu Pro Asp Arg Ala His Tyr Asn Ile
Val Thr Phe1 5 10 15
* * * * *